Yee, Brendon_V2

Prof Brendon Yee

Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services
Prof Brendon Yee is a Staff Specialist in Respiratory and Sleep Medicine and Medical Director of Respiratory Failure Services at Royal Prince Alfred Hospital. He is also a consultant for Rural Outreach Services in Sleep and Respiratory Medicine in Central Western NSW, previous Chair of the Professional Standards Committee of the Thoracic Society of Australia and New Zealand and a member of the Clinical Committee of the Australasian Sleep Association.Prof Yee is a graduate of the University of Otago, New Zealand and completed his sleep fellowship in Wellington, New Zealand and then Royal Prince Alfred Hospital, Sydney. He has a PhD from his research on the metabolic effects of sleep apnea and the effect of weight loss, and is a previous Young Investigator Award Winner of the Australasian Sleep Association.

More from this expert

Clinical Articles iconClinical Articles

With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

How is Restless Legs Syndrome (RLS) diagnosed, what other conditions need to be excluded, when should you treat RLS and what with, and when should you refer

Podcasts iconPodcasts

Prof Brendon Yee presents the latest evidence and recommendations for the use of GLP-1 agonists.

Podcasts iconPodcasts

Prof Brendon Yee explains how GPs and specialists can work together.

Podcasts iconPodcasts

Prof Brendon Yee addresses the questions on sleep studies and CPAP. 

Podcasts iconPodcasts

Professor Brendon Yee provides an update on OSA and its association with obesity.

Podcasts iconPodcasts

Practical guidance on recognising subtle symptoms of OSA, initiating assessment, and determining fitness to drive...

Clinical Articles iconClinical Articles

With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

Clinical Articles iconClinical Articles

Upcoming Healthed Webcast

Final webcast for 2025! Why is LDL control important?

Tuesday 25th November, 7pm - 9pm AEDT

Speaker

A/Prof Ron Dick

Cardiologist

We invite you to our final webcast of 2025, where A/Prof Ron Dick will discuss the importance of LDL control in primary care. Earn up to 4 hours CPD. RACGP & ACRRM accredited.